Vitamin D and hypertension

Electrolyte and Blood Pressure

Volumn 15, Issue 1, 2017, Pages 1-11

  Jeong, Hye Yun ^a   Park, Kyung Mi ^a   Lee, Mi Jung ^a   Yang, Dong Ho ^a   Kim, Sang Hoon ^a   Lee, So Young ^a  

^a CHA University   (South Korea)

Author keywords

Hypertension; Mechanism; Physiology; Supplement; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PLACEBO; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR; YOGHURT;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; FLOW MEDIATED VASODILATATION; HUMAN; HYPERCALCEMIA; HYPERTENSION; INTERVENTION STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PRIMARY HYPERPARATHYROIDISM; PROTEIN SYNTHESIS; REVIEW; SINGLE DRUG DOSE; SUNLIGHT; SYSTOLIC BLOOD PRESSURE; ULTRAVIOLET B RADIATION; VASODILATATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 85035192230     PISSN: 17385997     EISSN: 20929935     Source Type: Journal    
DOI: 10.5049/EBP.2017.15.1.1     Document Type: Review

References (94)

1. Holick MF: High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81:353-373, 2006
2. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266-281, 2007
3. Lackland DT, Weber MA: Global burden of cardiovascular disease and stroke: hypertension at the core. Can J Cardiol 31:569-571, 2015
4. Forman JP, Giovannucci E, Holmes MD, et al.: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49:1063-1069, 2007
5. Wang TJ, Pencina MJ, Booth SL, et al.: Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511, 2008
6. Forman JP, Curhan GC, Taylor EN: Plasma 25-hydroxy-vitamin D levels and risk of incident hypertension among young women. Hypertension 52:828-832, 2008
7. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V: Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 87:136-141, 2008
8. Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 20:713-719, 2007
9. Sypniewska G, Pollak J, Strozecki P, et al.: 25-hydroxy-vitamin D, biomarkers of endothelial dysfunction and subclinical organ damage in adults with hypertension. Am J Hypertens 27:114-121, 2014
10. Lind L, Wengle B, Ljunghall S: Blood pressure is lowered by vitamin D (alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. A double-blind, placebo-controlled study. Acta Med Scand 222: 423-427, 1987
11. Lind L, Wengle B, Wide L, Sorensen OH, Ljunghall S: Hypertension in primary hyperparathyroidism--reduction of blood pressure by long-term treatment with vitamin D(alphacalcidol). A double-blind, placebo-controlled study. Am J Hypertens 1:397-402, 1988
12. Lind L, Wengle B, Wide L, Ljunghall S: Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertens 2:20-25, 1989
13. Scragg R, Khaw KT, Murphy S: Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 49:640-646, 1995
14. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C: Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86:1633-1637, 2001
15. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD: Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25:320-325, 2008
16. Margolis KL, Ray RM, Van Horn L, et al.: Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension 52:847-855, 2008
17. Nagpal J, Pande JN, Bhartia A: A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 26:19-27, 2009
18. Zittermann A, Frisch S, Berthold HK, et al.: Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 89:1321-1327, 2009
19. de Zeeuw D, Agarwal R, Amdahl M, et al.: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543-1551, 2010
20. Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME: The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail 3:195-201, 2010
21. Witham MD, Dove FJ, Dryburgh M, et al.: The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 53:2112-2119, 2010
22. Shab-Bidar S, Neyestani TR, Djazayery A, et al.: Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial. BMC Med 9:125, 2011
23. Alvarez JA, Law J, Coakley KE, et al.: High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 96: 672-679, 2012
24. Gepner AD, Ramamurthy R, Krueger DC, et al.: A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One 7:e36617, 2012
25. Heshmat R, Tabatabaei-Malazy O, Abbaszadeh-Ahranjani S, et al.: Effect of vitamin D on insulin resistance and anthropometric parameters in Type 2 diabetes; a randomized double-blind clinical trial. Daru 20:10, 2012
26. Muldowney S, Lucey AJ, Hill TR, et al.: Incremental cholecalciferol supplementation up to 15 mug/d throughout winter at 51-55 degrees N has no effect on biomarkers of cardiovascular risk in healthy young and older adults. J Nutr 142:1519-1525, 2012
27. Salehpour A, Shidfar F, Hosseinpanah F, et al.: Vitamin D3 and the risk of CVD in overweight and obese women: a randomised controlled trial. Br J Nutr 108:1866-1873, 2012
28. Stricker H, Tosi Bianda F, Guidicelli-Nicolosi S, Limoni C, Colucci G: Effect of a single, oral, high-dose vitamin D supplementation on endothelial function in patients with peripheral arterial disease: a randomised controlled pilot study. Eur J Vasc Endovasc Surg 44:307-312, 2012
29. Witham MD, Dove FJ, Sugden JA, Doney AS, Struthers AD: The effect of vitamin D replacement on markers of vascular health in stroke patients - a randomised controlled trial. Nutr Metab Cardiovasc Dis 22:864-870, 2012
30. Wood AD, Secombes KR, Thies F, et al.: Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT. J Clin Endocrinol Metab 97:3557-3568, 2012
31. Breslavsky A, Frand J, Matas Z, et al.: Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients. Clin Nutr 32:970-975, 2013
32. Chai W, Cooney RV, Franke AA, Bostick RM: Effects of calcium and vitamin D supplementation on blood pressure and serum lipids and carotenoids: a randomized, double-blind, placebo-controlled, clinical trial. Ann Epidemiol 23:564-570, 2013
33. Forman JP, Scott JB, Ng K, et al.: Effect of vitamin D supplementation on blood pressure in blacks. Hypertension 61:779-785, 2013
34. Larsen T, Mose FH, Bech JN, Pedersen EB: Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial. BMC Nephrol 14:163, 2013
35. Toxqui L, Blanco-Rojo R, Wright I, Perez-Granados AM, Vaquero MP: Changes in blood pressure and lipid levels in young women consuming a vitamin D-fortified skimmed milk: a randomised controlled trial. Nutrients 5: 4966-4977, 2013
36. Wamberg L, Kampmann U, Stodkilde-Jorgensen H, et al.: Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels - results from a randomized trial. Eur J Intern Med 24:644-649, 2013
37. Witham MD, Adams F, Kabir G, et al.: Effect of short-term vitamin D supplementation on markers of vascular health in South Asian women living in the UK--a randomised controlled trial. Atherosclerosis 230:293-299, 2013
38. Witham MD, Dove FJ, Khan F, et al.: Effects of vitamin D supplementation on markers of vascular function after myocardial infarction--a randomised controlled trial. Int J Cardiol 167:745-749, 2013
39. Yiu YF, Yiu KH, Siu CW, et al.: Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. Atherosclerosis 227:140-146, 2013
40. Dalbeni A, Scaturro G, Degan M, Minuz P, Delva P: Effects of six months of vitamin D supplementation in patients with heart failure: a randomized double-blind controlled trial. Nutr Metab Cardiovasc Dis 24:861-868, 2014
41. Scragg R, Slow S, Stewart AW, et al.: Long-term high-dose vitamin D3 supplementation and blood pressure in healthy adults: a randomized controlled trial. Hypertension 64:725-730, 2014
42. Strobel F, Reusch J, Penna-Martinez M, et al.: Effect of a randomised controlled vitamin D trial on insulin resistance and glucose metabolism in patients with type 2 diabetes mellitus. Horm Metab Res 46:54-58, 2014
43. Sollid ST, Hutchinson MY, Fuskevag OM, et al.: No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with pre-diabetes. Diabetes Care 37:2123-2131, 2014
44. Wang AY, Fang F, Chan J, et al.: Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. J Am Soc Nephrol 25:175-186, 2014
45. Witham MD, Ireland S, Houston JG, et al.: Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial. Hypertension 63:706-712, 2014
46. Jo I, Ahn Y, Lee J, et al.: Prevalence, awareness, treatment, control and risk factors of hypertension in Korea: the Ansan study. J Hypertens 19:1523-1532, 2001
47. Norman AW: From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88:491s-499s, 2008
48. Calvo MS, Whiting SJ, Barton CN: Vitamin D intake: a global perspective of current status. J Nutr 135:310-316, 2005
49. Lips P, Hosking D, Lippuner K, et al.: The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 260:245-254, 2006
50. Heaney RP: Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 80:1706s-1709s, 2004
51. Holick MF, Siris ES, Binkley N, et al.: Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90:3215-3224, 2005
52. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586-1591, 2007
53. Chun RF: New perspectives on the vitamin D binding protein. Cell Biochem Funct 30:445-456, 2012
54. Cooke NE, Haddad JG: Vitamin D binding protein (Gc-globulin). Endocr Rev 10:294-307, 1989
55. Tanaka Y, Deluca HF: The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 154:566-574, 1973
56. Holick MF: Resurrection of vitamin D deficiency and rickets. J Clin Invest 116:2062-2072, 2006
57. DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80:1689s-1696s, 2004
58. Henry HL: Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 25:531-541, 2011
59. Coetzee M, Kruger MC: Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment? South Med J 97:506-511, 2004
60. Poole KE, Reeve J: Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 5:612-617, 2005
61. Blaine J, Chonchol M, Levi M: Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol 10:1257-1272, 2015
62. Juppner H: Phosphate and FGF-23. Kidney Int Suppl: S24-27, 2011
63. Nair R, Maseeh A: Vitamin D: The “sunshine” vitamin. J Pharmacol Pharmacother 3:118-126, 2012
64. Beveridge LA, Struthers AD, Khan F, et al.: Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data. JAMA Intern Med 175:745-754, 2015
65. Qi D, Nie X, Cai J: The effect of vitamin D supplementation on hypertension in non-CKD populations: A systemic review and meta-analysis. Int J Cardiol 227:177-186, 2017
66. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH: Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res 116:960-975, 2015
67. Forman JP, Williams JS, Fisher ND: Plasma 25-hydroxy-vitamin D and regulation of the renin-angiotensin system in humans. Hypertension 55:1283-1288, 2010
68. Santoro D, Caccamo D, Lucisano S, et al.: Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system. Biomed Res Int 2015:145828, 2015
69. Burgess ED, Hawkins RG, Watanabe M: Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens 3:903-905, 1990
70. Li YC, Kong J, Wei M, et al.: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238, 2002
71. Zhou C, Lu F, Cao K, et al.: Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice. Kidney Int 74:170-179, 2008
72. Yuan W, Pan W, Kong J, et al.: 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282:29821-29830, 2007
73. Harrison DG, Guzik TJ, Lob HE, et al.: Inflammation, immunity, and hypertension. Hypertension 57:132-140, 2011
74. Guzik TJ, Hoch NE, Brown KA, et al.: Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204:2449-2460, 2007
75. Crowley SD, Song YS, Lin EE, et al.: Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 298: R1089-1097, 2010
76. Tran LT, MacLeod KM, McNeill JH: Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats. Mol Cell Biochem 330:219-228, 2009
77. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP: IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol 27:2576-2581, 2007
78. Hartupee J, Liu C, Novotny M, Li X, Hamilton T: IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 179:4135-4141, 2007
79. Sakaguchi S, Ono M, Setoguchi R, et al.: Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8-27, 2006
80. Yin K, Agrawal DK: Vitamin D and inflammatory diseases. J Inflamm Res 7:69-87, 2014
81. Tarcin O, Yavuz DG, Ozben B, et al.: Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 94: 4023-4030, 2009
82. Lee SY, Kim HY, Gu SW, Kim HJ, Yang DH: 25-hydroxy-vitamin D levels and vascular calcification in predialysis and dialysis patients with chronic kidney disease. Kidney Blood Press Res 35:349-354, 2012
83. Ko EJ, Kim BH, Jeong HY, et al.: Serum 25-hydroxyvitamin D as a predictor of hospitalization-free survival in predialysis and dialysis patients with chronic kidney disease: a single-center prospective observational analysis. Kidney Res Clin Pract 35:22-28, 2016
84. Chitalia N, Recio-Mayoral A, Kaski JC, Banerjee D: Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis 220:265-268, 2012
85. Zhang QY, Jiang CM, Sun C, et al.: Hypovitaminosis D is associated with endothelial dysfunction in patients with non-dialysis chronic kidney disease. J Nephrol 28: 471-476, 2015
86. Andrukhova O, Slavic S, Zeitz U, et al.: Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol 28:53-64, 2014
87. Lind L, Pollare T, Hvarfner A, et al.: Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 11:141-147, 1989
88. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM: Ultraviolet B and blood pressure. Lancet 352:709-710, 1998
89. Pan WH, Wang CY, Li LA, Kao LS, Yeh SH: No significant effect of calcium and vitamin D supplementation on blood pressure and calcium metabolism in elderly Chinese. Chin J Physiol 36:85-94, 1993
90. Salehpour A, Hosseinpanah F, Shidfar F, et al.: A 12-week double-blind randomized clinical trial of vitamin D(3) supplementation on body fat mass in healthy overweight and obese women. Nutr J 11:78, 2012
91. Wu SH, Ho SC, Zhong L: Effects of vitamin D supplementation on blood pressure. South Med J 103:729-737, 2010
92. Kunutsor SK, Burgess S, Munroe PB, Khan H: Vitamin D and high blood pressure: causal association or epiphenomenon? Eur J Epidemiol 29:1-14, 2014
93. Jorde R, Sneve M, Torjesen P, Figenschau Y: No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 267:462-472, 2010
94. Witham MD, Price RJ, Struthers AD, et al.: Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med 173:1672-1679, 2013